Based on these positive results, pemigatinib was recently approved by the United States Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the second-line treatment of patients with advanced iCCA and FGFR2 fusion/rearrangements. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.